Do Peptides Stop Working? Tolerance, Receptor Desensitization, and Cycling Protocols Explained

If you have been running a peptide for weeks or months and feel like the effects have faded, you are not imagining it — but you might be misattributing the cause. Tolerance to peptides is real, but it is not universal. It depends entirely on the receptor system involved, the specific peptide's pharmacology, and how the body adapts to repeated stimulation of a given pathway. Growth hormone secretagogues like ipamorelin and CJC-1295 can produce attenuated GH pulses over time due to somatostatin feedback and pituitary desensitization. GLP-1 receptor agonists like semaglutide generally do not lose efficacy — the appetite suppression may feel less dramatic as you adapt, but the metabolic effects remain measurable. BPC-157 does not appear to develop tolerance in animal studies, even with extended administration. And GHRP-6, which was one of the earliest growth hormone-releasing peptides studied, shows clear tachyphylaxis (rapid tolerance) at high doses in research dating back to the 1990s. So the answer is not a simple yes or no. It depends on the peptide, the dose, the duration, and — critically — whether what you are interpreting as tolerance is actually something else entirely: your body reaching a new set point, your subjective perception normalizing, or a degraded peptide that has lost potency. This article covers the receptor pharmacology behind desensitization, which peptides are most and least prone to it, practical cycling strategies grounded in the research, and how to distinguish real tolerance from other explanations. Disclaimer: this is educational content based on published research. It is not medical advice. Work with a qualified healthcare provider for any protocol decisions.

To understand why some peptides lose effect and others do not, you need a basic grasp of receptor pharmacology. Most peptides work by binding to G-protein coupled receptors (GPCRs) on cell surfaces. When a peptide binds its receptor, it triggers an intracellular signaling cascade — increased cAMP, calcium release, gene transcription, whatever the downstream effect is. The body has built-in mechanisms to prevent overstimulation of these pathways, and those mechanisms are what create tolerance. The first mechanism is receptor phosphorylation and arrestin binding. Within minutes of activation, intracellular kinases (GRKs — G-protein receptor kinases) phosphorylate the activated receptor. This recruits beta-arrestin proteins, which physically block the receptor from coupling to its G-protein. The receptor is still on the cell surface, still bound to the peptide, but it cannot signal. This is called homologous desensitization — the receptor's own activation triggers its own shutdown. It is fast (minutes to hours) and reversible once the agonist clears. The second mechanism is receptor internalization. The beta-arrestin-bound receptor gets pulled into the cell interior via clathrin-coated pits — a process called endocytosis. Once internalized, the receptor can either be recycled back to the cell surface (resensitization) or routed to lysosomes for degradation (downregulation). Recycling takes hours. Degradation means the cell has to synthesize entirely new receptors, which takes days. The balance between recycling and degradation varies by receptor type and is a major determinant of whether tolerance is short-lived or prolonged. The third mechanism is downstream pathway adaptation. Even if the receptor continues to fire normally, the intracellular machinery can adapt. For GH secretagogues, a key example is somatostatin upregulation. When you repeatedly stimulate large GH pulses, the hypothalamus increases somatostatin tone to counterbalance the excess GH. The GH-releasing peptide is still activating its receptor just fine — but the downstream GH release is blunted because somatostatin is actively suppressing it. This is not receptor desensitization in the classical sense; it is a systems-level feedback adaptation. Understanding which mechanism is at play tells you how to address it. Receptor phosphorylation and arrestin binding resolve quickly — a day or two off may be enough. Internalization with degradation requires longer breaks. Downstream pathway adaptation (like somatostatin upregulation) requires strategic cycling with attention to the feedback system's time constants.

Growth hormone secretagogues (GHS) are the class most associated with tolerance concerns, but the picture varies significantly within the class. GHRP-6, one of the earliest studied, showed clear tachyphylaxis in a 1995 study by Huhn et al. published in the Journal of Clinical Endocrinology & Metabolism — GH response to repeated GHRP-6 boluses declined by roughly 50% over four days of continuous administration. GHRP-2 showed less tachyphylaxis in comparable studies, and ipamorelin, a more selective GH secretagogue that does not significantly raise cortisol or prolactin, appears to have the most favorable tolerance profile of the ghrelin mimetics. A 2001 study in the European Journal of Endocrinology found that ipamorelin maintained GH-releasing efficacy over 15 days of daily dosing without significant attenuation. CJC-1295 with DAC (drug affinity complex) is a long-acting GHRH analog with a half-life of approximately 6-8 days. Because it provides continuous GHRH receptor stimulation rather than pulsatile, there has been concern about receptor downregulation. Clinical data from the JeT-36 study (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) showed sustained IGF-1 elevation over 60-90 days of weekly dosing, suggesting that meaningful receptor downregulation did not occur at the doses studied. However, many anecdotal reports from the research community suggest diminishing subjective effects (improved sleep quality, recovery) after 3-4 months of continuous use. Whether this reflects true receptor desensitization, somatostatin adaptation, or subjective normalization is debated. GLP-1 receptor agonists like semaglutide are interesting because they cause receptor internalization — the GLP-1 receptor is internalized after activation — yet clinical efficacy is maintained long-term. The STEP trials demonstrated sustained weight loss over 68 weeks with semaglutide 2.4 mg weekly, with no evidence of tolerance to the metabolic effects. The likely explanation: GLP-1 receptors recycle efficiently back to the cell surface, and the drug's long half-life (approximately 7 days) provides sustained rather than pulsatile receptor occupancy, which may actually favor resensitization during the troughs. Patients do report that the initial dramatic appetite suppression fades — but this is likely hedonic adaptation (your brain adjusting to the new appetite set point) rather than receptor tolerance. BPC-157 (Body Protection Compound-157) does not appear to develop tolerance based on available evidence. Animal studies using BPC-157 for tendon healing, gut repair, and neuroprotection have administered the peptide for weeks to months without loss of efficacy. A 2018 study in the Journal of Physiology-Paris demonstrated sustained gastroprotective effects of BPC-157 over extended dosing periods in rats. The mechanism likely relates to BPC-157's action through the nitric oxide system and FAK-paxillin pathway rather than a single GPCR — broader mechanism peptides tend to be less prone to single-receptor desensitization. Melatonin-related peptides and other signaling peptides each have their own profiles. The key takeaway: do not assume all peptides behave the same way regarding tolerance. Track your response over time — Dosed makes this straightforward by letting you log doses and subjective markers on the same timeline, so you can see exactly when efficacy starts to shift.

Cycling — taking planned breaks from a peptide to allow receptor resensitization — is the most common strategy for managing tolerance. But cycling protocols should be informed by the pharmacology, not arbitrary. Here is what makes sense based on the mechanisms discussed above. For GH secretagogues (ipamorelin, GHRP-2, tesamorelin, CJC-1295 without DAC): the standard community protocol is 5 days on, 2 days off. This allows GRK/arrestin-mediated desensitization to reverse (which takes hours to a day) and gives somatostatin tone a brief window to normalize. A more conservative approach is 4 weeks on, 1-2 weeks off, which addresses longer-term somatostatin adaptation. There is no single correct answer — the 5/2 protocol is sufficient for some, while others find they need monthly breaks to maintain peak GH response. Monitoring IGF-1 levels at baseline, at 4 weeks, and at 12 weeks gives you objective data on whether your GH axis response is being maintained. For CJC-1295 with DAC specifically: because of the long half-life, the 5/2 protocol does not make pharmacokinetic sense — the drug is still active during the two days off. Monthly cycling (3 weeks on, 1 week off) or quarterly cycling (10-12 weeks on, 2-4 weeks off) aligns better with the drug's pharmacology. Some providers use CJC-1295 with DAC for 3-6 month blocks followed by 4-6 week breaks. For GLP-1 receptor agonists: cycling is generally not recommended from an efficacy standpoint. The clinical data supports continuous use, and stopping and restarting introduces the nausea and GI side effects of the titration phase all over again. If a patient feels the appetite suppression has diminished, the clinical approach is dose adjustment rather than cycling. For BPC-157: most protocols run 4-8 week courses targeted at a specific healing goal, with breaks between courses. This is less about tolerance (which does not appear to be an issue) and more about the principle of targeted intervention — you use it while healing, then stop when the therapeutic goal is achieved. Some people run longer courses for chronic gut issues, and there is no strong evidence that extended use becomes less effective. The most important thing — and the part most people skip — is actually tracking what is happening. Subjective perception of tolerance is notoriously unreliable. You get used to feeling good, and the new normal stops feeling remarkable. That is not the same as the peptide losing efficacy. If you are running a GH secretagogue and your sleep quality improved dramatically in week one, by week eight you have forgotten what bad sleep felt like. Your sleep is still better — you have just adapted psychologically to the improvement. This is where logging in Dosed becomes genuinely useful. When you track daily doses alongside subjective ratings (sleep quality, recovery, appetite, mood, injection site reactions), you create an objective record that cuts through subjective drift. You can look back at week one and week twelve and compare actual ratings rather than relying on memory, which is biased toward noticing decline. If your sleep quality rating genuinely dropped from 8/10 to 5/10 over 12 weeks at the same dose, that is a signal worth investigating. If it went from 8/10 to 7/10, that might just be noise. One more critical point: before assuming tolerance, rule out peptide degradation. A peptide that has been reconstituted for six weeks, or stored at room temperature, or exposed to light, may have lost significant potency. If your effects suddenly dropped off rather than gradually fading, degradation is more likely than receptor desensitization. Check your storage conditions, reconstitution date, and whether the solution has become cloudy or changed color. Replacing the vial with a fresh one is the cheapest diagnostic test available.